An improved plaque reduction virus neutralization assay for human metapneumovirus

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Virus-neutralizing antibodies are crucial for protection against human metapneumovirus (hMPV).
• Existing assays for detecting hMPV-specific neutralizing antibodies can be time-consuming and less sensitive.
• Antigenic variability in hMPV necessitates robust methods for vaccine development.

Purpose of the Study:

• To design and validate an improved plaque reduction virus neutralization assay for detecting hMPV-specific neutralizing antibodies.
• To evaluate the utility of recombinant hMPV strains expressing green fluorescent protein (GFP) for assay development.
• To assess the impact of F gene mutations on hMPV replication and assay performance.

Main Methods:

• Developed a plaque reduction virus neutralization assay using two recombinant hMPV strains expressing GFP.
• Investigated hMPV mutants with trypsin-independent replication.
• Compared the improved assay with a conventional virus neutralization assay using sera from ferrets, hamsters, and macaques.

Main Results:

• The improved assay detected hMPV-specific neutralizing antibodies effectively using GFP expression.
• Recombinant hMPV strains replicated in vitro, with trypsin enhancing plaque size.
• The new assay demonstrated agreement with the conventional method but was faster, 10-fold more sensitive, and suitable for high-throughput testing.

Conclusions:

• An improved plaque reduction virus neutralization assay using GFP-expressing hMPV is a sensitive and efficient tool for detecting hMPV immunity.
• This assay is valuable for research, vaccine development, and high-throughput screening.
• The assay's enhanced sensitivity aids in understanding protective immunity against hMPV.